Literature DB >> 8772584

Aging and bone metabolism in African American and Caucasian women.

H M Perry1, M Horowitz, J E Morley, S Fleming, J Jensen, P Caccione, D K Miller, F E Kaiser, M Sundarum.   

Abstract

There is limited information concerning bone mineral density (BMD) and its determinants across a wide spectrum of ages in African American females (AAF). Therefore, we have performed a cross-sectional study of 54 AAF and 39 Caucasian females (CF), aged 20-90 yr, to quantify femoral and lumbar bone mineral density, total body calcium, as well as the potential determinants of bone density. BMD decreased with age in all sites after age 40 yr in both racial groups. Bone density was greater in AAF than in CF, although there was considerable overlap between the two groups. There was no significant difference in the rate of age-related bone loss between the two groups. At the femoral neck, BMD was below the fracture threshold in 28% of the postmenopausal AAF compared to 47% of postmenopausal CF. L1-L4 BMD was below the fracture threshold in 8% of postmenopausal AAF and 11% of postmenopausal CF. Serum-25 hydroxyvitamin D (25OHD) was inversely related to age in both othnic groups and lower (P < 0.05) in premenopausal AAF than CF. Twenty-four percent of the AAF and 22% of the CF had serum 25OHD levels of 8 ng/L or less. Serum PTH was directly related to age (r = 0.43; P = 0.003 in AAF and r = 0.55; P = 0.002 in CF), and 25OHD was inversely related to age (r = -0.43; P = 0.003 in AAF and r = -0.65; P < 0.001 in CF). PTH was higher (P < 0.05) in postmenopausal AAF than in CF. Serum testosterone was greater in AAF than in CF (P < 0.05). Serum estradiol was greater in premenopausal AAF than in CF. Serum dehydroepiandrosterone sulfate was inversely related to age (r = 0.42; P = 0.004 in AAF and r = 0.51; P = 0.005 in CF). Serum osteocalcin was related to age in AAF (r = 0.47; P = 0.001), but not in CF. There was also a trend for an increase in urinary dipyridinoline (expressed per 100 mg urinary creatinine) with age (r = 0.31; P = 0.055 in AAF and r = 0.37; P = 0.066 in CF). Both lean and fat mass were major determinants of femoral neck BMD in AAF. Femoral BMD was directly related to body weight and body mass index in both races. Serum 25OHD and dehydroepiandrosterone sulfate approached statistical significance as independent predictors of femoral BMD in AAF. We conclude that in AAF, 1) bone density is higher than in CF, but there is a significant risk of fracture in a substantial number of subjects on the basis of BMD; 2) there is no difference in rates of age-related bone loss compared to those in CF; 3) both lean and fat mass are significant determinants of bone density; 4) serum estradiol and testosterone were higher than those in CF; and 5) aging is associated with increased bone turnover, 25OHD deficiency, and secondary hyperparathyroidism in both races. The absence of a difference in rates of bone loss between AAF and CF despite higher serum levels of PTH is compatible with the concept of a relative skeletal resistance to PTH in AAF.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8772584     DOI: 10.1210/jcem.81.3.8772584

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  17 in total

1.  High prevalence of low vitamin D and musculoskeletal complaints in women with breast cancer.

Authors:  Nicola Napoli; Swapna Vattikuti; Cynthia Ma; Antonella Rastelli; Anitha Rayani; Ravi Donepudi; Mohammadreza Asadfard; Jayasree Yarramaneni; Matthew Ellis; Reina Armamento-Villareal
Journal:  Breast J       Date:  2010 Nov-Dec       Impact factor: 2.431

2.  The impact of clothing style on bone mineral density among women in Turkey.

Authors:  D Alper Hayirlioglu; Husnu Gokaslan; Canan Cimsit; N Ozden Serin
Journal:  Rheumatol Int       Date:  2007-11-16       Impact factor: 2.631

3.  Lean body mass, not estrogen or progesterone, predicts peak bone mineral density in premenopausal women.

Authors:  Lee-Jane W Lu; Fatima Nayeem; Karl E Anderson; James J Grady; Manubai Nagamani
Journal:  J Nutr       Date:  2008-12-23       Impact factor: 4.798

4.  Evidence that increased ovarian aromatase activity and expression account for higher estradiol levels in African American compared with Caucasian women.

Authors:  N D Shaw; S S Srouji; C K Welt; K H Cox; J H Fox; J M Adams; P M Sluss; J E Hall
Journal:  J Clin Endocrinol Metab       Date:  2013-11-27       Impact factor: 5.958

5.  Socioeconomic status, race, and bone turnover in the Midlife in the US Study.

Authors:  C J Crandall; D Miller-Martinez; G A Greendale; N Binkley; T E Seeman; A S Karlamangla
Journal:  Osteoporos Int       Date:  2011-08-03       Impact factor: 4.507

6.  Estrogen therapy and bone mineral density in African-American and Caucasian women.

Authors:  Susan L Eskridge; Deborah J Morton; Donna Kritz-Silverstein; Elizabeth Barrett-Connor; Deborah Wingard; Wilma Wooten
Journal:  Am J Epidemiol       Date:  2010-02-23       Impact factor: 4.897

7.  Estrogen levels are higher across the menstrual cycle in African-American women compared with Caucasian women.

Authors:  E E Marsh; N D Shaw; K M Klingman; T O Tiamfook-Morgan; M A Yialamas; P M Sluss; J E Hall
Journal:  J Clin Endocrinol Metab       Date:  2011-08-17       Impact factor: 5.958

8.  Inter-population variation of histomorphometric variables used in the estimation of age-at-death.

Authors:  D Botha; N Lynnerup; M Steyn
Journal:  Int J Legal Med       Date:  2019-04-09       Impact factor: 2.686

9.  Utilization of preoperative patient factors to predict postoperative vitamin D deficiency for patients undergoing gastric bypass.

Authors:  Judy Jin; Thomas A Stellato; Peter T Hallowell; Margaret Schuster; Kristen Graf; Scott Wilhelm
Journal:  J Gastrointest Surg       Date:  2009-03-13       Impact factor: 3.452

10.  Fracture rates in urban South African children of different ethnic origins: the Birth to Twenty cohort.

Authors:  K Thandrayen; S A Norris; J M Pettifor
Journal:  Osteoporos Int       Date:  2008-05-09       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.